Circled by rival pharma giants and a biotech powerhouse, Kodiak asks for a $100M-plus IPO for new eye drug
Kodiak Sciences was never one of those biotechs that liked to tout every financing round or talk up its drug prospects. Helmed by biotech vet …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
